A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

Key Inclusion Criteria:

• Active or chronic active AMR (biopsy-confirmed) without TCMR per central reading, asdefined by the Banff 2022 criteria.

• Kidney transplant at least 6 months prior to Screening visit (recipients of eitherliving or deceased donors).

• Donor-specific antibody (DSA): Human leukocyte antigen (HLA) Class I and/or IIantigen-specific DSA-positive (preformed and/or de novo DSA) as determined by thelocal laboratory's definition of positivity using single-antigen bead-based assayswithin 3 months prior to randomization.

Key Exclusion Criteria:

• Transplant: Blood type (ABO)-incompatible transplant.

• History of multiple organ transplants including en bloc and dual kidney transplants.

• Acute, rapid decline in renal function, defined as a participant likely to requirerenal replacement therapy within the subsequent 30 days as determined by theInvestigator.

• Treatment: Prior AMR/TCMR treatment (with the exception of corticosteroids) within 3months prior to randomization is excluded as listed below. Participants who receivedany of these treatments between 3 and 6 months prior to randomization must have botha renal biopsy (IC3) and DSA testing at least 6 weeks after completing (or stopping)treatment in order to confirm continuing AMR and to determine eligibility:

1. Intravenous or subcutaneous immunoglobulin (IVIg or subcutaneous immunoglobulin [SCIg]) or PLEX.

2. Complement system inhibitors (e.g., eculizumab).

3. Proteasome inhibitors (e.g., bortezomib).

4. Tocilizumab.

5. Any other investigational agent within 3 months or 5 half-lives (whichever islonger) of randomization.

Other protocol-defined inclusion/exclusion criteria apply.